{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:31:07Z","timestamp":1790379067792,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-75675-5","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:46:28Z","timestamp":1784137588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["IL7-Receptor\u2013Targeted CAR T-Cell Therapy for T-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.1038","volume":"17","author":[{"given":"Hocine R.","family":"Hocine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Undrakh","family":"Ganbaatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6406-3565","authenticated-orcid":false,"given":"Alfredo","family":"Amador-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srijita","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Misawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratiti","family":"Ankola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9964-5877","authenticated-orcid":false,"given":"Christina","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuquan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-2336","authenticated-orcid":false,"given":"William-Ray","family":"Vista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Y.","family":"Bellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4229-0977","authenticated-orcid":false,"given":"Navin K.","family":"Chintala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Sulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2903-5130","authenticated-orcid":false,"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9091-488X","authenticated-orcid":false,"given":"Andrew L.","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-2046","authenticated-orcid":false,"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"75675_CR1","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMra023001","volume":"350","author":"CH Pui","year":"2004","unstructured":"Pui, C. H., Relling, M. V. & Downing, J. R. Acute lymphoblastic leukemia. N. Engl. J. Med. 350, 1535\u20131548 (2004).","journal-title":"N. Engl. J. Med"},{"key":"75675_CR2","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1200\/JCO.2003.10.116","volume":"21","author":"JM Goldberg","year":"2003","unstructured":"Goldberg, J. M. et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J. Clin. Oncol. 21, 3616\u20133622 (2003).","journal-title":"J. Clin. Oncol."},{"key":"75675_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/CCO.0b013e32834f5c41","volume":"24","author":"SK Khaled","year":"2012","unstructured":"Khaled, S. K., Thomas, S. H. & Forman, S. J. Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. Curr. Opin. Oncol. 24, 182\u2013190 (2012).","journal-title":"Curr. Opin. Oncol."},{"key":"75675_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/bloodadvances.2023010303","volume":"8","author":"S Shimony","year":"2024","unstructured":"Shimony, S., DeAngelo, D. J. & Luskin, M. R. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia. Blood Adv. 8, 23\u201336 (2024).","journal-title":"Blood Adv."},{"key":"75675_CR5","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/ajh.25957","volume":"95","author":"A Candoni","year":"2020","unstructured":"Candoni, A. et al. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma. A CAMPUS ALL study. Am. J. Hematol. 95, 1466\u20131472 (2020).","journal-title":"Am. J. Hematol."},{"key":"75675_CR6","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1182\/blood.2019000553","volume":"138","author":"A Silva","year":"2021","unstructured":"Silva, A. et al. Overexpression of wild-type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia\/lymphoma. Blood 138, 1040\u20131052 (2021).","journal-title":"Blood"},{"key":"75675_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.3","volume":"7","author":"P Richter-Pechanska","year":"2017","unstructured":"Richter-Pechanska, P. et al. Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia. Blood Cancer J. 7, e523 (2017).","journal-title":"Blood Cancer J."},{"key":"75675_CR8","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/s41375-019-0685-4","volume":"34","author":"R Kim","year":"2020","unstructured":"Kim, R. et al. Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. Leukemia 34, 1730\u20131740 (2020).","journal-title":"Leukemia"},{"key":"75675_CR9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood-2023-186699","volume":"142","author":"L Courtois","year":"2023","unstructured":"Courtois, L. et al. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition. Blood 142, 158\u2013171 (2023).","journal-title":"Blood"},{"key":"75675_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nature10725","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157\u2013163 (2012).","journal-title":"Nature"},{"key":"75675_CR11","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/genes12081118","volume":"12","author":"V Bardelli","year":"2021","unstructured":"Bardelli, V. et al. T-cell acute lymphoblastic leukemia: biomarkers and their clinical usefulness. Genes (Basel) 12, 1118 (2021).","journal-title":"Genes (Basel)"},{"key":"75675_CR12","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/s41375-022-01590-5","volume":"36","author":"ML Oliveira","year":"2022","unstructured":"Oliveira, M. L. et al. Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia. Leukemia 36, 1533\u20131540 (2022).","journal-title":"Leukemia"},{"key":"75675_CR13","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/3877","volume":"20","author":"A Puel","year":"1998","unstructured":"Puel, A., Ziegler, S. F., Buckley, R. H. & Leonard, W. J. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat. Genet 20, 394\u2013397 (1998).","journal-title":"Nat. Genet"},{"key":"75675_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.cytogfr.2005.05.004","volume":"16","author":"Q Jiang","year":"2005","unstructured":"Jiang, Q. et al. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev. 16, 513\u2013533 (2005).","journal-title":"Cytokine Growth Factor Rev."},{"key":"75675_CR15","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1084\/jem.20110580","volume":"208","author":"C Shochat","year":"2011","unstructured":"Shochat, C. et al. Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. J. Exp. Med. 208, 901\u2013908 (2011).","journal-title":"J. Exp. Med"},{"key":"75675_CR16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/ng.924","volume":"43","author":"PP Zenatti","year":"2011","unstructured":"Zenatti, P. P. et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat. Genet 43, 932\u2013939 (2011).","journal-title":"Nat. Genet"},{"key":"75675_CR17","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/s41375-019-0434-8","volume":"33","author":"P Akkapeddi","year":"2019","unstructured":"Akkapeddi, P. et al. A fully human anti-IL-7Ralpha antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia. Leukemia 33, 2155\u20132168 (2019).","journal-title":"Leukemia"},{"key":"75675_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41375-019-0531-8","volume":"34","author":"JA Hixon","year":"2020","unstructured":"Hixon, J. A. et al. New anti-IL-7Ralpha monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models. Leukemia 34, 35\u201349 (2020).","journal-title":"Leukemia"},{"key":"75675_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41591-024-03282-2","volume":"31","author":"J Pan","year":"2025","unstructured":"Pan, J. et al. Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial. Nat. Med. 31, 126\u2013136 (2025).","journal-title":"Nat. Med"},{"key":"75675_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40164-024-00584-6","volume":"13","author":"H Zheng","year":"2024","unstructured":"Zheng, H. et al. Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies. Exp. Hematol. Oncol. 13, 117 (2024).","journal-title":"Exp. Hematol. Oncol."},{"key":"75675_CR21","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood.2025029299","volume":"146","author":"J Pan","year":"2025","unstructured":"Pan, J. et al. Donor-derived CD7 CAR T cells for pediatric and adult relapsed\/refractory T-ALL\/LBL: a phase 2 trial. Blood 146, 2745\u20132757 (2025).","journal-title":"Blood"},{"key":"75675_CR22","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","volume":"30","author":"BLZ Oh","year":"2024","unstructured":"Oh, B. L. Z. et al. Fratricide-resistant CD7-CAR T cells in T-ALL. Nat. Med 30, 3687\u20133696 (2024).","journal-title":"Nat. Med"},{"key":"75675_CR23","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1182\/bloodadvances.2023012263","volume":"9","author":"N Maciocia","year":"2025","unstructured":"Maciocia, N., Wade, B. & Maciocia, P. CAR T-cell therapies for T-cell malignancies: does cellular immunotherapy represent the best chance of cure? Blood Adv. 9, 913\u2013923 (2025).","journal-title":"Blood Adv."},{"key":"75675_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva, D. et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 130, 285\u2013296 (2017).","journal-title":"Blood"},{"key":"75675_CR25","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1182\/blood.2023022204","volume":"143","author":"LC Hill","year":"2024","unstructured":"Hill, L. C. et al. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas. Blood 143, 1231\u20131241 (2024).","journal-title":"Blood"},{"key":"75675_CR26","first-page":"321","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu, P. et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood 140, 321\u2013334 (2022).","journal-title":"Blood"},{"key":"75675_CR27","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s43018-023-00573-4","volume":"4","author":"Y Xiong","year":"2023","unstructured":"Xiong, Y. et al. c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation. Nat. Cancer 4, 1001\u20131015 (2023).","journal-title":"Nat. Cancer"},{"key":"75675_CR28","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli, P. S. et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 11, 2748\u20132763 (2021).","journal-title":"Cancer Discov."},{"key":"75675_CR29","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1182\/blood.2021015020","volume":"140","author":"A Freiwan","year":"2022","unstructured":"Freiwan, A. et al. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood 140, 2684\u20132696 (2022).","journal-title":"Blood"},{"key":"75675_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03797-7","volume":"20","author":"Y Lu","year":"2022","unstructured":"Lu, Y. et al. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R\/R-AML). J. Transl. Med. 20, 600 (2022).","journal-title":"J. Transl. Med"},{"key":"75675_CR31","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 e3529 (2021).","journal-title":"Cell"},{"key":"75675_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1786","volume":"372","author":"EW Weber","year":"2021","unstructured":"Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 372, eaba1786 (2021).","journal-title":"Science"},{"key":"75675_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","volume":"31","author":"N Watanabe","year":"2023","unstructured":"Watanabe, N. et al. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies. Mol. Ther. 31, 24\u201334 (2023).","journal-title":"Mol. Ther."},{"key":"75675_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","volume":"26","author":"CE Brown","year":"2018","unstructured":"Brown, C. E. et al. Optimization of IL13Ralpha2-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma. Mol. Ther. 26, 31\u201344 (2018).","journal-title":"Mol. Ther."},{"key":"75675_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05063-4","volume":"22","author":"T Poiret","year":"2024","unstructured":"Poiret, T., Vikberg, S., Schoutrop, E., Mattsson, J. & Magalhaes, I. CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude. J. Transl. Med. 22, 273 (2024).","journal-title":"J. Transl. Med"},{"key":"75675_CR36","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2016-03-679209","volume":"128","author":"SD Cramer","year":"2016","unstructured":"Cramer, S. D., Aplan, P. D. & Durum, S. K. Therapeutic targeting of IL-7Ralpha signaling pathways in ALL treatment. Blood 128, 473\u2013478 (2016).","journal-title":"Blood"},{"key":"75675_CR37","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1126\/science.8266077","volume":"262","author":"M Noguchi","year":"1993","unstructured":"Noguchi, M. et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science 262, 1877\u20131880 (1993).","journal-title":"Science"},{"key":"75675_CR38","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1182\/blood-2012-08-451278","volume":"122","author":"K Yokoyama","year":"2013","unstructured":"Yokoyama, K. et al. In vivo leukemogenic potential of an interleukin 7 receptor alpha chain mutant in hematopoietic stem and progenitor cells. Blood 122, 4259\u20134263 (2013).","journal-title":"Blood"},{"key":"75675_CR39","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.2012.45.2052","volume":"31","author":"K Suzuki","year":"2013","unstructured":"Suzuki, K. et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3\/CD3 ratio are independent predictors of recurrence. J. Clin. Oncol. 31, 490\u2013498 (2013).","journal-title":"J. Clin. Oncol."},{"key":"75675_CR40","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","volume":"75","author":"HG Caruso","year":"2015","unstructured":"Caruso, H. G. et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 75, 3505\u20133518 (2015).","journal-title":"Cancer Res"},{"key":"75675_CR41","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.ymthe.2017.04.017","volume":"25","author":"S Arcangeli","year":"2017","unstructured":"Arcangeli, S. et al. Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia. Mol. Ther. 25, 1933\u20131945 (2017).","journal-title":"Mol. Ther."},{"key":"75675_CR42","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","volume":"25","author":"E Drent","year":"2017","unstructured":"Drent, E. et al. A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization. Mol. Ther. 25, 1946\u20131958 (2017).","journal-title":"Mol. Ther."},{"key":"75675_CR43","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","volume":"75","author":"X Liu","year":"2015","unstructured":"Liu, X. et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 75, 3596\u20133607 (2015).","journal-title":"Cancer Res"},{"key":"75675_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14749-3","volume":"7","author":"S Park","year":"2017","unstructured":"Park, S. et al. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Sci. Rep. 7, 14366 (2017).","journal-title":"Sci. Rep."},{"key":"75675_CR45","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel, J. Y. et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat. Med. 27, 1419\u20131431 (2021).","journal-title":"Nat. Med"},{"key":"75675_CR46","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.4049\/jimmunol.180.4.2107","volume":"180","author":"CD Hammerbeck","year":"2008","unstructured":"Hammerbeck, C. D. & Mescher, M. F. Antigen controls IL-7R alpha expression levels on CD8 T cells during full activation or tolerance induction. J. Immunol. 180, 2107\u20132116 (2008).","journal-title":"J. Immunol."},{"key":"75675_CR47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/sj.gt.3301051","volume":"7","author":"ME Weijtens","year":"2000","unstructured":"Weijtens, M. E., Hart, E. H. & Bolhuis, R. L. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther. 7, 35\u201342 (2000).","journal-title":"Gene Ther."},{"key":"75675_CR48","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1097\/CJI.0b013e3180de5d90","volume":"30","author":"F Turatti","year":"2007","unstructured":"Turatti, F. et al. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J. Immunother. 30, 684\u2013693 (2007).","journal-title":"J. Immunother."},{"key":"75675_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2024.103529","volume":"6","author":"L Rosselle","year":"2025","unstructured":"Rosselle, L. et al. Protocol for production of tonic CAR T cells with dasatinib. STAR Protoc. 6, 103529 (2025).","journal-title":"STAR Protoc."},{"key":"75675_CR50","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 32, 995\u20131007 (2022).","journal-title":"Cell Res"},{"key":"75675_CR51","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04538599 (2025). RD13-01 for Patients With r\/r CD7+ T\/NK Cell Hematologic Malignancies. ClinicalTrials.gov identifier: NCT04538599. Updated January 25, 2021. Accessed February 25."},{"key":"75675_CR52","unstructured":"CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed\/ Refractory T-Lineage Acute Lymphoblastic Leukaemia. ClinicalTrials.gov identifier: NCT05043571. Updated September 14, 2021. Accessed February 25, 2025. https:\/\/clinicaltrials.gov\/study\/ NCT05043571."},{"key":"75675_CR53","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","volume":"126","author":"M Mamonkin","year":"2015","unstructured":"Mamonkin, M., Rouce, R. H., Tashiro, H. & Brenner, M. K. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood 126, 983\u2013992 (2015).","journal-title":"Blood"},{"key":"75675_CR54","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1038\/s41375-023-02039-z","volume":"37","author":"J Xiang","year":"2023","unstructured":"Xiang, J. et al. An \u201coff-the-shelf\u201d CD2 universal CAR-T therapy for T-cell malignancies. Leukemia 37, 2448\u20132456 (2023).","journal-title":"Leukemia"},{"key":"75675_CR55","doi-asserted-by":"publisher","first-page":"56219","DOI":"10.18632\/oncotarget.11019","volume":"7","author":"KH Chen","year":"2016","unstructured":"Chen, K. H. et al. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Oncotarget 7, 56219\u201356232 (2016).","journal-title":"Oncotarget"},{"key":"75675_CR56","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41592-020-0862-4","volume":"17","author":"M Mukhopadhyay","year":"2020","unstructured":"Mukhopadhyay, M. Macrophages enter CAR immunotherapy. Nat. Methods 17, 561 (2020).","journal-title":"Nat. Methods"},{"key":"75675_CR57","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","volume":"13","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J. Hematol. Oncol. 13, 153 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"75675_CR58","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/nm.4444","volume":"23","author":"PM Maciocia","year":"2017","unstructured":"Maciocia, P. M. et al. Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies. Nat. Med. 23, 1416\u20131423 (2017).","journal-title":"Nat. Med"},{"key":"75675_CR59","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1182\/blood-2018-10-882944","volume":"133","author":"D Sanchez-Martinez","year":"2019","unstructured":"Sanchez-Martinez, D. et al. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood 133, 2291\u20132304 (2019).","journal-title":"Blood"},{"key":"75675_CR60","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13045-021-01178-z","volume":"14","author":"J Shi","year":"2021","unstructured":"Shi, J. et al. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. J. Hematol. Oncol. 14, 162 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"75675_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood.2021013648","volume":"140","author":"PM Maciocia","year":"2022","unstructured":"Maciocia, P. M. et al. Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia. Blood 140, 25\u201337 (2022).","journal-title":"Blood"},{"key":"75675_CR62","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907","volume":"11","author":"K Mestermann","year":"2019","unstructured":"Mestermann, K. et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci. Transl. Med. 11, eaau5907 (2019).","journal-title":"Sci. Transl. Med"},{"key":"75675_CR63","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.omto.2021.06.006","volume":"22","author":"MS Skovgard","year":"2021","unstructured":"Skovgard, M. S. et al. Imaging CAR T-cell kinetics in solid tumors: Translational implications. Mol. Ther. Oncolytics 22, 355\u2013367 (2021).","journal-title":"Mol. Ther. Oncolytics"},{"key":"75675_CR64","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1158\/2326-6066.CIR-22-0840","volume":"11","author":"HT Quach","year":"2023","unstructured":"Quach, H. T. et al. Tumor-targeted nonablative radiation promotes solid tumor CAR T-cell therapy efficacy. Cancer Immunol. Res 11, 1314\u20131331 (2023).","journal-title":"Cancer Immunol. Res"},{"key":"75675_CR65","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/CJI.0b013e318194a6e8","volume":"32","author":"D Hollyman","year":"2009","unstructured":"Hollyman, D. et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J. Immunother. 32, 169\u2013180 (2009).","journal-title":"J. Immunother."},{"key":"75675_CR66","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky, L. et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest 126, 3130\u20133144 (2016).","journal-title":"J. Clin. Invest"},{"key":"75675_CR67","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","volume":"6","author":"PS Adusumilli","year":"2014","unstructured":"Adusumilli, P. S. et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 6, 261ra151 (2014).","journal-title":"Sci. Transl. Med"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75675-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75675-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75675-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:02:19Z","timestamp":1787223739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75675-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75675"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75675-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.S.A. declares research funding from Novocure; Scientific Advisory Board Member and\/or Consultant for Affyimmune Therapeutics, Bio4t2, Carisma Therapeutics, Century Therapeutics, Orion Pharma, Outpace Bio, Pluri-biotech, and Verismo Therapeutics; patents, royalties, and intellectual property on mesothelin-targeted CAR and other T-cell therapies, issued patent method for detection of cancer cells using virus, and pending patent applications on PD-1 dominant negative receptor, wireless pulse-oximetry device, and on an ex vivo malignant pleural effusion culture system. Memorial Sloan Kettering Cancer Center has previously licensed intellectual property related to mesothelin-targeted CARs and T-cell therapies to ATARA Biotherapeutics and had associated financial interests. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8692"}}